[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-293843-105":59,"doc-detail-293843-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","introducing-the-mmpi-3-presentation-agenda-development-and-scales-overview","INTRODUCING THE MMPI-3 - Presentation Agenda - Development and Scales Overview","","Presentation outlining the development and core components of the MMPI-3, led by Patrick Moran, Ph.D., Pearson Clinical Assessment. It covers preliminary studies comparing dichotomous versus polytomous response formats, outcomes of item clarification and rewording, and item development using expert consultation, trial item creation, and empirical retention criteria. The agenda further introduces the MMPI-3 structure, including key scales and norms, plus references to manuals, user’s guides, and data collection plans supporting scale development, validation, comparisons, and normative data in English, Spanish, and bilingual forms.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":20,"@type":76,"position":81},"https://docshare.wps.com/document/exam/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/introducing-the-mmpi-3-presentation-agenda-development-and-scales-overview/293843/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/introducing-the-mmpi-3-presentation-agenda-development-and-scales-overview/293843.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver Hayes","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-17",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What response format did the preliminary studies evaluate for the MMPI-3?","Question",{"text":113,"@type":114},"The presentation compares dichotomous (T/F) versus polytomous response formats and reports that reliability estimates and systematic error differ under the polytomous approach. The stated conclusion is to retain the T/F response format for the MMPI-3.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were existing items improved before finalizing the MMPI-3 item pool?",{"text":118,"@type":114},"The preliminary work included reviewing MMPI-2-RF items for awkward or dated wording, simplifying content, and conducting item analyses. The presentation reports specific rewording counts and notes that empirical correlates were unaffected.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the purpose of item development in creating MMPI-3 trial items?",{"text":122,"@type":114},"Item development aimed to identify content missing from or insufficiently represented in the MMPI-2-RF item pool. The method combined consultation with MMPI-2-RF experts, review of existing measures, development of 135 trial items, internal analyses, and retention of 90 plus five replacement trial items as candidates for MMPI-3 inclusion.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},293843,1789969464,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":19,"category_name":20,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687207020761,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","INTRODUCING THE MMPI-3  \nPatrick Moran, Ph.D. Pearson Clinical Assessment  \nAgenda  \n􀂅 MMPI-3 Development  \n􀂅 The MMPI-3  \n􀂆 Scales  \n􀂆 Norms  \n􀂆 Manuals and User’s Guides  \nMMPI-3 Development  \nPreliminary Studies  \n􀂅 A series of studies to explore ideas and questions for MMPI-3 development  \n􀂅  Response Format (n=406):  \n􀂆 Dichotomous (T/F) versus Polytomous  \n􀂄 Definitely True  \n􀂄 Mostly True  \n􀂄 Mostly False  \n􀂄 Definitely False  \n􀂆 Polytomous response format:  \n􀂄 Small increases in reliability estimates  \n􀂄 No improvement in scale score validities  \n􀂄 Likely reflecting increased systematic error  \n􀂆 Conclusion: Retain T/F response format for MMPI-3  \nPreliminary Studies  \n􀂅  Item Improvement (n=552)  \n􀂆 Content clarification, simplification  \n􀂆 338 MMPI-2-RF items reviewed for  \n􀂄 Awkward/dated wording  \n􀂄 Potential simplification  \nI love to go ~~to dances ~~dancing.  \nI am ~~apt to take~~ likely to feel disappointments so ~~keenly ~~strongly that I can't put them out of my mind.  \n􀂆 53 items reworded  \n􀂆 Following item analyses 43 revisions retained  \n􀂆 Empirical correlates unaffected  \nPreliminary Studies  \n􀂅  Item Development  \n􀂆 Objective: Identify content missing from, orinsufficiently represented by, the MMPI-2-RF item pool  \n􀂆 Method:  \n􀂄 Consultation with 12 MMPI-2-RF experts  \n􀂄 Review of existing measures  \n􀂄 Development of 135 Trial Items  \nPreliminary Studies  \n􀂅  Item Development Study (N=519)  \n􀂄 Internal item analyses and correlations with external criteria  \n􀂄 90 of 135 trial items retained  \n􀂄 5 replacement trial items developed  \n􀂅 Outcome: 95 trial items, candidates for inclusion on MMPI-3  \nDevelopment Plan  \n􀂅 MMPI-2-RF-EX  \n􀂆 Brief Biographical Questionnaire  \n􀂆 338 MMPI-2-RF items (43 updated)  \n􀂆 95 Trial Items  \n􀂆 Booklet and answer sheet  \n􀂅 Q Local EX  \n􀂅 All new material translated into Spanish  \n􀂆 Garcia/Azan MMPI-2/RF translation starting point  \n􀂆 Rewritten and Trial items translated by Dr. Antonio E. Puente and Team at UNCWilmington  \nDevelopment Plan  \n􀂅 Data Collection:  \n􀂆 Field Data  \n􀂄 Sites represent settings in which MMPI is used  \n􀂄 Mental health, medical, forensic, public safety  \n􀂄 Used for:  \n􀂄 Scale Development  \n􀂄 Validation  \n􀂄 Comparison Groups  \n􀂆 College Studies  \n􀂄 Initial psychometric analyses  \n􀂄 Detailed Validation Analyses  \n􀂆 Normative Data  \n􀂄 English  \n􀂄 Spanish  \n􀂄 Bilingual","cbCaim4TRLznObag","https://ap.wps.com/l/cbCaim4TRLznObag","pdf",2275968,74,"English","# Agenda\n## MMPI-3 Development\n## The MMPI-3\n## Scales\n## Norms\n## Manuals and User’s Guides","[{\"question\":\"What response format did the preliminary studies evaluate for the MMPI-3?\",\"answer\":\"The presentation compares dichotomous (T/F) versus polytomous response formats and reports that reliability estimates and systematic error differ under the polytomous approach. The stated conclusion is to retain the T/F response format for the MMPI-3.\"},{\"question\":\"How were existing items improved before finalizing the MMPI-3 item pool?\",\"answer\":\"The preliminary work included reviewing MMPI-2-RF items for awkward or dated wording, simplifying content, and conducting item analyses. The presentation reports specific rewording counts and notes that empirical correlates were unaffected.\"},{\"question\":\"What was the purpose of item development in creating MMPI-3 trial items?\",\"answer\":\"Item development aimed to identify content missing from or insufficiently represented in the MMPI-2-RF item pool. The method combined consultation with MMPI-2-RF experts, review of existing measures, development of 135 trial items, internal analyses, and retention of 90 plus five replacement trial items as candidates for MMPI-3 inclusion.\"}]","INTRODUCING THE MMPI-3 - Presentation Agenda - Development and Scales Overview | PDF",1789669344,186]